Wegovy in Northern Ireland: what's actually available and how to get it

You've looked it up online and the waiting lists sound endless, here's why

Picture this: you've spoken to your GP, they've acknowledged your weight is affecting your health, and they've mentioned Wegovy but said the referral pathway is complicated. That's the reality for most people in Northern Ireland right now. Unlike NHS England, which has published phased rollout criteria under NICE technology appraisals, the HSC in Northern Ireland has no equivalent commissioned pathway that mirrors those timelines. Specialist weight-management clinics exist, but they carry long waiting lists, and the referral thresholds are set by individual trusts. Semaglutide prescribed through the HSC for weight management is not widely available at GP level.

This matters because NICE's appraisal of semaglutide (TA875) technically applies to England. Scotland, Wales and Northern Ireland make their own decisions, and Northern Ireland's HSC has not yet replicated the NHS England rollout structure for GLP-1 weight-loss medicines. If you want to understand how access compares elsewhere in Britain, the Wegovy in England page and the Wegovy in Scotland page both set out those respective systems in detail. For a closer look at whether Wegovy is available in Northern Ireland and what the current HSC position means in practice, that page goes into the detail specific to this region. For Northern Ireland, the practical upshot is that private prescription is the realistic near-term route for most people who qualify clinically.

What the private prescription route looks like from a Northern Ireland address

A private prescription for Wegovy is entirely legal anywhere in the UK, Northern Ireland included. You consult a clinician (in person or through a GPhC-registered online pharmacy) who assesses your medical history, current weight, BMI, and any relevant conditions. If semaglutide is appropriate for you, a prescription is issued and a pharmacy dispenses it. The medicine itself is identical to what would be dispensed on the NHS: genuine, MHRA-regulated, sourced through the licensed UK supply chain.

At nume, every consultation is read by a GPhC-registered Independent Prescriber the same day, a real clinician, not automated screening. If you order before noon on a weekday, treatment approved that day is dispatched the same afternoon and delivered free the next working day by DPD. Worth bearing in mind if you're timing things around payday or planning ahead of a bank holiday: the 12pm cut-off is the key window. Packaging is plain and unbranded. There are no subscriptions and no auto-renewals; every repeat order is clinically re-reviewed before anything is sent. You can read more about who we are and how the pharmacy is run if you want to check our credentials before starting.

One point worth flagging: a GPhC-registered online pharmacy can legally dispense to a Northern Ireland address. You can verify any online pharmacy's registration at the GPhC pharmacy register, it takes about thirty seconds and is the single most reliable check you can do.

Who qualifies for Wegovy on a private prescription in Northern Ireland

The eligibility criteria come from the medicine's UK licence, not from HSC commissioning rules. Adults with a BMI of 30 or above qualify as a baseline. Adults with a BMI between 27 and 29.9 may also be eligible if they have at least one weight-related condition, for example, high blood pressure, type 2 diabetes, high cholesterol, obstructive sleep apnoea or cardiovascular disease. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI is a starting point, not a guarantee: the prescriber reviews the full clinical picture, including any contraindications, before issuing a prescription.

Wegovy is not licensed for anyone under 18, is not recommended during pregnancy or breastfeeding, and is not suitable for people who are trying to conceive. Conditions such as a history of pancreatitis or certain thyroid cancers require careful prescriber discussion. The full Wegovy overview page covers the eligibility criteria in more depth if you want to go through the detail before your consultation. You can also explore the broader weight-loss treatment options side by side to see whether semaglutide or tirzepatide is likely the better clinical fit for you.

What to expect from treatment: the semaglutide titration path and common side effects

Wegovy starts at 0.25mg weekly. Most people move up through 0.5mg, 1.0mg and 1.7mg before reaching the 2.4mg maintenance dose, with roughly four weeks at each level. A newer 7.2mg maintenance dose was approved by the MHRA in April 2026; whether that's appropriate is a decision made at consultation, not something you choose off a menu. The titration exists to reduce side effects, going slowly matters.

The most common side effects are gastrointestinal: nausea, loose stools, indigestion and reduced appetite are all frequently reported, particularly in the first few weeks of a new dose. Most people find these settle once the body adjusts. Occasionally people feel persistently cold on treatment, there's a specific page on that if it's something you're already wondering about. More serious but less common effects include gallbladder problems and, rarely, pancreatitis. Seek urgent medical attention for severe stomach pain radiating to the back. All side effects can be reported directly to the MHRA via the Yellow Card scheme. The NHS patient information for semaglutide at nhs.uk/medicines/semaglutide is a reliable plain-English reference to read alongside your Patient Information Leaflet. The is Wegovy worth it page looks at the evidence for results if you want to weigh up the clinical case before committing. And if cost is part of the decision, the Wegovy cost page sets out what you'd typically pay privately and what's bundled into a legitimate price.